Repository logo
Andean Publishing ↗
New user? Click here to register. Have you forgotten your password?
  1. Home
  2. Browse by Author

Browsing by Autor "Analio Dugarte-Dugarte"

Filter results by typing the first few letters
Now showing 1 - 1 of 1
  • Results Per Page
  • Sort Options
  • Loading...
    Thumbnail Image
    Item type: Item ,
    The crystal structures of methoxmetamine hydrochloride and methoxetamine hydrochloride determined from laboratory X-ray powder diffraction data contained in the Powder Diffraction File <sup>™</sup>
    (Cambridge University Press, 2025) Analio Dugarte-Dugarte; Jacco van de Streek; Graciela Dı́az de Delgado; Joel W. Reid; Bronislav Jurásek; Martin Kuchař; Martin Babor; José Miguel Delgado
    Abstract The crystal structures of two arylcyclohexylamine derivatives – methoxmetamine·HCl (2-(3-methoxyphenyl)-2-(methylamino)cyclohexan-1-one hydrochloride, MMXE·HCl) and methoxetamine·HCl (2-(ethylamino)-2-(3-methoxyphenyl)cyclohexan-1-one hydrochloride, MXE·HCl) – have been determined using laboratory X-ray powder diffraction data contained in the Powder Diffraction File ™ . MMXE·HCl and MXE·HCl exhibit anesthetic and sedative effects and have been illicitly used as recreational drugs due to their dissociative hallucinogenic and euphoriant effects. The structure determination of MMXE·HCl and MXE·HCl was carried out with DASH, and the Rietveld refinements were performed with TOPAS Academic in monoclinic unit cells. The parameters obtained for MMXE·HCl were a = 15.0429(5) Å, b = 14.0721(5) Å, c = 6.5716(2) Å, β = 90.9864(14)°, and V = 1,390.91(8) Å 3 , with Z = 4 and space group P 2 1 / n. The parameters obtained for MXE·HCl were a = 8.7772(5) Å, b = 9.9528(7) Å, c = 8.5841(6) Å, β = 100.276(3)°, and V = 737.86(8) Å 3 , with Z = 2 and space group P 2 1 . The structures were validated by dispersion-corrected DFT calculations. Hirshfeld surface analysis and fingerprint plots calculations are also reported.

Andean Library © 2026 · Andean Publishing

  • Accessibility settings
  • Privacy policy
  • End User Agreement
  • Send Feedback